drugset
drugset / Trial / NCT02654821

Study With T-cel Receptor Gene Therapy in Metastatic Melanoma

NCT02654821 ↗

Phase 1/2 Unknown 12 enrolled The Netherlands Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

Patients with stage IV melanoma (also eye melanoma) will be treated with TCR transduced cells.

Timeline

Start
2012-03
Primary completion
2019-10
Completion
2020-01

Drugs

EvaluationDrugModalityDoseRoute
Subject TCR-transduced T cells Cell therapy 5e+07 cells Intravenous
Subject TCR-transduced T cells Cell therapy 1e+08 cells Intravenous
Subject TCR-transduced T cells Cell therapy 2.5e+08 cells Intravenous
Subject TCR-transduced T cells Cell therapy 1e+09 cells Intravenous

Indications

cutaneous melanoma ocular melanoma